Study design (if review, criteria of inclusion for studies)
randomized trial
Participants
9 patients with mucoviscidosis
Interventions
inhale in randomised sequence physiological saline solution with and without addition of amiloride. Mucociliary clearance was then measured over a period of 60 minutes, followed by active coughing for one minute. Subsequently, physiological saline solution was inhaled for 10 minutes, followed by active coughing-off.
Outcome measures
Mucociliary clearance, cough clearance
Main results
It was shown that mucociliary clearance is significantly accelerated by amiloride administration (approx. 0.07 mg) (p < 0.05). Cough clearance also increased significantly after amiloride administration (p < 0.05). Subsequent inhalation of 0.09% NaCl solution did not result in further acceleration of tussive clearance.
Authors' conclusions
The results show that in mucoviscidosis cough clearance is significantly restricted, not, however, the mucociliary clearance. Hence, particular emphasis will be placed in future on active coughing-off following inhalation of aerosolised amiloride that did not produce any side effects. Substances related to amiloride, and especially those with longer-lasting action, may therefore bring about a significant improvement of this therapeutic aproach to cystic fibrosis.
Keywords: Amiloride; exercise; Inhalation OR nebulised; non pharmacological intervention - devices OR physiotherapy; pharmacological_intervention; Airway clearance drugs -expectorants- mucolytic- mucociliary-; ENaC antagonists - Sodium Channel Blockers; Respiratory System Agents;